Rezolute (RZLT) Total Non-Current Liabilities (2011 - 2020)
Rezolute (RZLT) posted Total Non-Current Liabilities of $3.6 million for Q2 2020, down 17.49% sequentially from $4.4 million in Q1 2020, and up 69.73% YoY from $2.1 million in Q3 2019.
Rezolute (RZLT) Total Non-Current Liabilities (2011 - 2020) Analysis & Trends
Rezolute has reported Total Non-Current Liabilities for 8 years, with the latest figure at $3.6 million in Q2 2020.
- Quarterly Total Non-Current Liabilities rose 69.73% year-over-year to $3.6 million in Q2 2020, while the trailing twelve-month figure through Jun 2020 was $3.6 million (up 69.73% YoY) and the FY2020 annual result came in at $3.6 million, up 69.73% from the prior year.
- Total Non-Current Liabilities declined to $3.6 million in Q2 2020 per RZLT's latest filing, from $4.4 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $10.8 million in Q1 2019 and troughed at $173270.0 in Q3 2018.
- A 5-year average of $2.6 million and a median of $383925.5 in 2016 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2019 and 2020: Total Non-Current Liabilities jumped 4443.42% in 2019, then tumbled 59.55% in 2020.
- Over 5 years, Total Non-Current Liabilities stood at $335588.0 in 2016, then retreated by 19.92% to $268732.0 in 2017, then surged by 3711.74% to $10.2 million in 2018, then plunged by 43.09% to $5.8 million in 2019, then slumped by 38.24% to $3.6 million in 2020.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $3.6 million, $4.4 million, and $5.8 million for Q2 2020, Q1 2020, and Q4 2019 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Rezolute | 442.94 Mn | 442.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 3.60 Mn |
| Mar 31, 2020 | 4.36 Mn |
| Dec 31, 2019 | 5.83 Mn |
| Sep 30, 2019 | 5.87 Mn |
| Jun 30, 2019 | 2.12 Mn |
| Mar 31, 2019 | 10.79 Mn |
| Dec 31, 2018 | 10.24 Mn |
| Sep 30, 2018 | 173,270.00 |
| Jun 30, 2018 | 215,623.00 |
| Mar 31, 2018 | 237,404.00 |
| Dec 31, 2017 | 268,732.00 |
| Sep 30, 2017 | 299,176.00 |
| Jun 30, 2017 | 329,621.00 |
| Mar 31, 2017 | 314,655.00 |
| Dec 31, 2016 | 335,588.00 |
| Sep 30, 2016 | 367,813.00 |
| Jun 30, 2016 | 400,038.00 |
| Mar 31, 2016 | 431,341.00 |
| Dec 31, 2015 | 460,794.00 |
| Sep 30, 2015 | 453,586.00 |